Nonalcoholic steatohepatitis (NASH) is a common preneoplastic condition of hepatocellular carcinoma (HCC). Mice with hepatocytic deletion of Pten develop NASH and HCC later in life. This model is highly valuable for studies aimed at identifying the molecular mechanism by which metabolic disorders contribute to tumor development. We applied proteomic and lipidomic profiling approaches to Pten-null NASH liver and tumors. Circulating fatty acid composition was also characterized in these mice. The relevance to human NASH and HCC was further validated. This integrative proteomic and lipidomic study from mouse to human and from liver to blood identified the following disease signatures: (i) an HCC signature: upregulated hepatic scd1/scd2, fads2,...
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome in the liver....
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatt...
The association of nonalcoholic steatohepatitis (NASH) with obesity and type 2 diabetes is a major d...
To uncover mechanisms of nonalcoholic steatohepatitis (NASH) associated hepatocarcinogenesis, we com...
With the rising incidence of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH...
Objective. Metabolic alteration is widely considered as one of the hallmarks of cancer. Hepatocellul...
Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of hepatocellular ...
Hepatocellular carcinoma (HCC) is the second most deadly cancer worldwide, which can result from the...
Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in We...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
Metabolic dysfunction is associated with nonalcoholic steatohepatitis (NASH) development. However, o...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
The proportion of obese or diabetic population has been anticipated to increase in the upcoming deca...
Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of hepatocellular ...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome in the liver....
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatt...
The association of nonalcoholic steatohepatitis (NASH) with obesity and type 2 diabetes is a major d...
To uncover mechanisms of nonalcoholic steatohepatitis (NASH) associated hepatocarcinogenesis, we com...
With the rising incidence of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH...
Objective. Metabolic alteration is widely considered as one of the hallmarks of cancer. Hepatocellul...
Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of hepatocellular ...
Hepatocellular carcinoma (HCC) is the second most deadly cancer worldwide, which can result from the...
Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in We...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
Metabolic dysfunction is associated with nonalcoholic steatohepatitis (NASH) development. However, o...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
The proportion of obese or diabetic population has been anticipated to increase in the upcoming deca...
Non-alcoholic steatohepatitis (NASH) represents a risk factor for the development of hepatocellular ...
BackgroundDespite the global prevalence of nonalcoholic fatty liver disease (NAFLD), its pathophysio...
Non-alcoholic fatty liver disease (NAFLD) is a manifestation of the metabolic syndrome in the liver....
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatt...
The association of nonalcoholic steatohepatitis (NASH) with obesity and type 2 diabetes is a major d...